Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.67 |
| ▸ | GSTK1 | Q9Y2Q3 | 1/20 | 0.67 |
| ▸ | GLO1 | Q04760 | 5/20 | 0.62 |
| ▸ | NOD1 | Q9Y239 | 5/20 | 0.44 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.40 |
| ▸ | GRM8 | O00222 | 1/20 | 0.38 |
| ▸ | GRM6 | O15303 | 1/20 | 0.38 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.38 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.38 |
| ▸ | GSR | P00390 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.38 |
| ▸ | GRM5 | P41594 | 1/20 | 0.38 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.38 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.38 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.38 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.38 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.38 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.38 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18009307 | 1.00 | PTGS1 (0.67) | PTGS1GSTK1GLO1NOD1FOLH1 | |
| SCHEMBL14236615 | 1.00 | PTGS1 (0.67) | PTGS1GSTK1GLO1NOD1FOLH1 | |
| SCHEMBL420277 | 1.00 | PTGS1 (0.67) | PTGS1GSTK1GLO1NOD1FOLH1 | |
| Hydrochloric Acid SCHEMBL31197175 | 0.99 | PTGS1 (0.65) | PTGS1GSTK1GLO1NOD1FOLH1 | |
| Sulfuric Acid SCHEMBL31197174 | 0.95 | PTGS1 (0.61) | PTGS1GSTK1GLO1NOD1FOLH1 | |
| Aspartic Acid SCHEMBL31197177 | 0.95 | PTGS1 (0.61) | PTGS1GSTK1GLO1NOD1FOLH1 | |
| SCHEMBL19293445 | 0.89 | PTGS1 (0.65) | PTGS1GSTK1GLO1NOD1FOLH1 | |
| SCHEMBL5332446 | 0.89 | PTGS1 (0.68) | PTGS1GSTK1GLO1NOD1FOLH1 | |
| SCHEMBL5332441 | 0.89 | PTGS1 (0.68) | PTGS1GSTK1GLO1NOD1FOLH1 | |
| S-Methylglutathione SCHEMBL13157330 | 0.88 | PTGS1 (0.71) | PTGS1GSTK1GLO1NOD1FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 173 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260048091-A1 | COMPOSITIONS AND METHODS FOR IMPROVING GASTROINTESTINAL HEALTH IN A SUBJECT | CROSS III WILLIAM H (US) | 2026-02-19 | — | — | US | claimed |
| CN-119909065-A | Compositions and methods for treating and reducing alcohol-induced skin flushes | 布鲁菲斯特有限责任公司 | 2025-05-02 | — | — | CN | claimed |
| US-20250073201-A1 | COMPOSITIONS AND METHODS FOR TREATING ACUTE ALCOHOL INTAKE | NEXT LEVEL HEALTH SCIENCES INC (CA) | 2025-03-06 | — | — | US | claimed |
| CN-119015394-A | Sulfur-containing compound preparation, and preparation method and application thereof | 上海优斐斯生物科技有限公司 | 2024-11-26 | — | — | CN | claimed |
| EP-4452278-A1 | PHARMACEUTICAL COMPOSITION BASED ON GLUTATHIONE THIOESTER AND OLEUROPEIN FOR USE IN THE TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS | Innbiotec Pharma S.R.L. (IT) | 2024-10-30 | — | — | EP | claimed |
| US-20240307481-A1 | COMPOSITIONS AND METHODS FOR IMPROVING EYE FUNCTION | CROSS III WILLIAM H (US) | 2024-09-19 | — | — | US | claimed |
| EP-4412625-A1 | COMPOSITIONS AND METHODS FOR TREATING ACUTE ALCOHOL INTAKE | Next Level Health Sciences Inc. (CA) | 2024-08-14 | — | — | EP | claimed |
| CN-117398452-A | Composition prepared by eutectic technology and application thereof in improving activity of alcohol dehydrogenase and acetaldehyde dehydrogenase | 广东海赫生物医药科技有限公司 | 2024-01-16 | — | — | CN | claimed |
| WO-2023119167-A1 | PHARMACEUTICAL COMPOSITION BASED ON GLUTATHIONE THIOESTER AND OLEUROPEIN FOR USE IN THE TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS | INNBIOTEC PHARMA S.R.L. (IT) | 2023-06-29 | — | — | WO | claimed |
| EP-3919054-B1 | PHYTOTHERAPEUTIC COMPOSITIONS FOR TOPICAL OR ORAL USE IN ACNE TREATMENT | SESTITO FRANCESCO (IT) | 2023-06-14 | — | — | EP | claimed |
| EP-2948160-A1 | COMPOSITIONS CONTAINING CHONDROITIN SULPHATE, PROTEOLYTIC ENZYMES AND SULPHYDRYL COMPOUNDS FOR IMPROVING THE BIOAVAILABILITY OF CHONDROITIN SULPHATE | Gnosis S.p.A. (IT) | 2015-12-02 | — | — | EP | claimed |
| WO-2015067708-A1 | CRYSTALLINE FORMS OF S-ACETYL GLUTATHIONE, THEIR PREPARATIONS AND USES IN PHARMACEUTICAL AND NUTRACEUTICAL FORMULATIONS | GNOSIS S.P.A. (IT) | 2015-05-14 | — | — | WO | claimed |
| WO-2014114706-A1 | COMPOSITIONS CONTAINING CHONDROITIN SULPHATE, PROTEOLYTIC ENZYMES AND SULPHYDRYL COMPOUNDS FOR IMPROVING THE BIOAVAILABILITY OF CHONDROITIN SULPHATE | GNOSIS S.P.A. (IT) | 2014-07-31 | — | — | WO | claimed |
| US-20140100283-A1 | Method to Increase Absorption and Bioavailability of Oral Glutathione | Atlantic Pro Nutrients, Inc. dba XYMOGEN (US) | 2014-04-10 | — | — | US | claimed |
| EP-2664330-A1 | Composition and medication containing Omega 3 fatty acids and a glucosaminoglucan | F. Holzer GmbH (DE) | 2013-11-20 | — | — | EP | claimed |
| EP-2444083-A1 | Cysteine and food intake | Nestec S.A. (CH) | 2012-04-25 | — | — | EP | claimed |
| EP-1853292-B1 | PHARMACEUTICAL COMPOSITION COMPRISING GLUTATHIONE COMPOUNDS AND BETALAIN FOR THE PREVENTION AND TREATMENT OF CANCER | GERNOT TREUSCH (ES) | 2008-12-10 | — | — | EP | claimed |
| EP-1154784-B1 | THERAPEUTICALLY ACTIVE MIXTURE OF SUBSTANCES CONTAINING S-ACETYLGLUTATHIONE AND ACICLOVIR | TREUSCH GERNOT (ES) | 2002-10-23 | — | — | EP | claimed |
| EP-1154784-A1 | THERAPEUTICALLY ACTIVE MIXTURE OF SUBSTANCES CONTAINING S-ACETYLGLUTATHIONE AND ACICLOVIR | Treusch, Gernot (ES) | 2001-11-21 | — | — | EP | claimed |
| WO-2000050060-A1 | THERAPEUTICALLY ACTIVE MIXTURE OF SUBSTANCES CONTAINING S-ACETYLGLUTATHIONE AND ACICLOVIR | TREUSCH GERNOT (ES) | 2000-08-31 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260048091-A1 | COMPOSITIONS AND METHODS FOR IMPROVING GASTROINTESTINAL HEALTH IN A SUBJECT | GSS, GLS, GLS2 | PTGS1 44/4885GSTK1 20/4885GLO1 74/4885 |
| US-20140100283-A1 | Method to Increase Absorption and Bioavailability of Oral Glutathione | GSR, GSTP1, GSS | PTGS1 172/4885GSTK1 9/4885GLO1 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.